Markerii tumorali in screeningul cancerului
Frontiers | A Threshold Model for T-Cell Activation in the Era of Checkpoint Blockade Immunotherapy
Markeri tumorali in bolile digestive 0758751841 Cabinet privat de gastroenterologie si hepatologie Bucuresti | 0758751841 Cabinet privat de gastroenterologie si hepatologie Bucuresti
Frontiers | Redefining Tumor-Associated Macrophage Subpopulations and Functions in the Tumor Microenvironment
Cancers | Free Full-Text | Targeting Tumor Glycans for Cancer Therapy: Successes, Limitations, and Perspectives
Antitumor Effect by Hydroxyapatite Nanospheres: Activation of Mitochondria-Dependent Apoptosis and Negative Regulation of Phosphatidylinositol-3-Kinase/Protein Kinase B Pathway | ACS Nano
Monitoring and adapting cancer treatment using circulating tumor DNA kinetics: Current research, opportunities, and challenges | Science Advances
Cum folosesc markerii tumorali in diagnosticul bolilor digestive | | Clinica gastroenterologie-hepatologie dr Ditoiu Bucuresti
An Intelligent Biomimetic Nanoplatform for Holistic Treatment of Metastatic Triple-Negative Breast Cancer via Photothermal Ablation and Immune Remodeling | ACS Nano
Clinical Utility of Tumor Markers
Cum folosesc markerii tumorali in diagnosticul bolilor digestive | | Clinica gastroenterologie-hepatologie dr Ditoiu Bucuresti
Detection of glioma infiltration at the tumor margin using quantitative stimulated Raman scattering histology | Scientific Reports
MAPK pathway activation selectively inhibits ASCL1-driven small cell lung cancer - ScienceDirect
Outcomes of patients presenting with elevated tumor marker levels but negative gadoxetic acid-enhanced liver MRI after a complete response to hepatocellular carcinoma treatment | PLOS ONE
Tumor microenvironment: Challenges and opportunities in targeting metastasis of triple negative breast cancer - ScienceDirect
Frontiers | Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
Cancers | Free Full-Text | Tumor-Associated Macrophage Status in Cancer Treatment
Factors Associated With Receiving at Least One Tumor Marker Test in 2... | Download Table
C/EBPB-dependent adaptation to palmitic acid promotes tumor formation in hormone receptor negative breast cancer | Nature Communications
Systemic Therapy for Estrogen Receptor–Positive, HER2-Negative Breast Cancer | NEJM
TEM8 marks neovasculogenic tumor-initiating cells in triple-negative breast cancer | Nature Communications
A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging: Cell
